ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

Report this content

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a specific divisional U.S. patent was issued in 2018.

AdaptVac’s novel capsid virus-like particle (VLP) technology platform shows strong potential as a platform for the development of novel breakthrough vaccines and immunotherapies, including its first development project AV001, a treatment vaccine for HER2+ breast cancer. AV001 is now covered by both a divisional patent and the new platform patent in the United States, the largest single market for the project.

“This patent validation of the core VLP platform signifies great value for both the AV001 project itself, and the whole AdaptVac pipeline. AdaptVac will now stand better protected when entering into collaborations with world-class research groups to develop breakthrough solutions for some of the world’s most challenging unmet medical needs,” says ExpreS2ion’s CEO Bent U. Frandsen.

AV001: Strong global market potential in breast cancer
Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually, resulting in more than 450,000 deaths in 2015. Today the most common treatment for HER2 positive breast cancer is monoclonal antibodies, which generates annual global sales above US$ 7 billion. The target product profile of AdaptVac's lead breast cancer project, AV001, is tailored to be highly competitive in terms of cost and efficacy, thus aiming at a significant market share.

About AdaptVac ApS
AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, combining ExpreS2ion’s platform with novel proprietary and ground-breaking capsid virus-like particle (VLP) technology developed at the University of Copenhagen. The company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

For further information about ExpreS2ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on January 7, 2020.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatory validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.